Table 5.
Associations between SNPs and patients with SSc with different clinical characteristics.
| Clinical characteristics | rs117026326 (GTF2I) | rs73366469 (GTF2I) | rs1599961 (NFKB1) | rs2304256 (TYK2) | ||||
|---|---|---|---|---|---|---|---|---|
| P | OR | P | OR | P | OR | P | OR | |
| SSc–ILD vs SSc–non-ILD | 0.129 | 0.74 (0.50–1.09) | 0.179 | 0.77 (0.52–1.13) | 0.083 | 0.72 (0.50–1.04) | 0.426 | 1.15 (0.81–1.63) |
| SSc–ILD vs HC | 1.34E–04* | 0.58 (0.44–0.77) | 2.22E–04* | 1.66 (1.27–2.17) | 0.307 | 1.12 (0.90–1.38) | 0.97 | 1.00 (0.81–1.25) |
| SSc–non-ILD vs HC | 5.74E–06* | 2.38 (1.64–3.46) | 2.58E–05* | 2.18 (1.52–3.14) | 0.011* | 1.49 (1.09–2.02) | 0.388 | 0.87 (0.64–1.19) |
| SSc–PAH vs SSc–non-PAH | 0.99 | 1.0 (0.63–1.60) | 0.78 | 1.07 (0.67–1.70) | 0.796 | 1.06 (0.69–1.62) | 0.735 | 1.07 (0.71–1.61) |
| SSc–PAH vs HC | 3.54E–04* | 2.13 (1.41–3.23) | 3.10E–04* | 2.09 (1.40–3.12) | 0.081 | 1.34 (0.96–1.87) | 0.844 | 1.04 (0.74–1.46) |
| SSc–non-PAH vs HC | 1.46E–05* | 2.12 (1.51–2.99) | 7.37E–05* | 1.96 (1.40–2.73) | 0.074 | 1.28 (0.98–1.67) | 0.788 | 0.96 (0.73–1.27) |
| dcSSc vs lcSSc | 0.601 | 1.23 (0.57–2.68) | 0.68 | 1.17 (0.55–2.50) | 0.448 | 0.77 (0.39–1.51) | 0.134 | 0.61 (0.32–1.16) |
| ATA (+) vs ATA (–) | 0.088 | 0.66 (0.40–1.07) | 0.26 | 0.77 (048–1.22) | 0.72 | 1.09 (0.69–1.70) | 0.67 | 1.10 (0.72–1.67) |
| ACA (+) vs ACA (–) | 0.55 | 0.83 (0.46–1.51) | 0.86 | 0.95 (0.54–1.69) | 0.77 | 0.92 (0.52–1.62) | 0.51 | 0.84 (0.51–1.40) |
SSc, systemic sclerosis; HC, healthy controls; ILD, interstitial lung disease; PAH, pulmonary arterial hypertension; ATA, anti-topoisomerase I antibody; ACA, anti-centromere antibody. *The P value was still < 0.05 after Bonferroni correction.